| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Officers of Elevance Health, Inc. (the "Company") expect to speak with investors over the next week. During these meetings, Company officers expect to reaffirm the Company's shareholders' earnings guidance for full year 2025 to be approximately $24.70 per diluted share, including approximately $5.30 per diluted share of net unfavorable items. Excluding these items, the Company continues to expect adjusted shareholders' earnings to be approximately $30.00 per diluted share. This does not include any other adjustment items beyond those reported in the Company's third quarter 2025 earnings.
During these meetings, Company officers are also expected to reaffirm full year 2025 benefit expense ratio guidance of approximately 90.0%.
The Company notes that these expectations reflect management's current view of market conditions, operational performance, the regulatory and policy landscape, and refinement of key business assumptions, including cost trends and medical claims payable estimates. To the extent business factors or assumptions change, the Company's actual results could materially differ from management's current guidance.
Posted In: ELV
